Drisdol

Quick links to important sections

Drisdol

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drisdol

Property Description
Active ingredient Dihydrotachysterol (DHT)
Form Capsule, Oral Solution (Liquid)
Pharmacological class Vitamin D Analogue, Calcium Regulator
Route of administration Oral
Origin Synthetic (derived from Ergocalciferol)

Drisdol is a specialized prescription medication whose active ingredient is Dihydrotachysterol (DHT), primarily functioning as a potent Vitamin D Analogue and a Calcium Regulator. This compound is a synthetic seco-steroid that is chemically derived from Ergocalciferol (Vitamin D2).


What Type of Medicine is Drisdol?

Dihydrotachysterol is classified pharmacologically as a Vitamin D Analogue, a class clinically recognized for its essential role in managing mineral metabolism. The compound itself is a synthetic derivative, a reduced form that distinguishes it from Vitamin D2 and D3 because it begins working directly upon administration, without requiring the initial metabolic processing by the kidneys to become active. This distinction is crucial, allowing for precise and efficient regulation of mineral balance. The medication is supplied as a single-ingredient product for oral administration, typically available in capsule and oral solution (liquid) forms. The solution form is often compounded in an oil-based vehicle due to the compound's fat-soluble nature, which is particularly beneficial for individuals requiring strict dosing adjustments.


General Purpose of Dihydrotachysterol

The general purpose of Dihydrotachysterol is to maintain the essential stability of the body’s mineral environment. It works by promoting the absorption of calcium from the intestines and mobilizing it from bone stores, thereby ensuring sufficient calcium is available in the bloodstream. This potent action serves to address conditions related to chronic mineral imbalance by effectively substituting for the body's natural Vitamin D regulation process. By ensuring adequate calcium levels, Dihydrotachysterol supports numerous involuntary physiological processes, including proper neuromuscular function and the structural integrity of the skeleton, contributing to overall physiological stability.

Regulatory References

  1. DrugBank Dihydrotachysterol
  2. Vitamin D Analogue

What side effects are possible with Drisdol ?

The safety profile of Dihydrotachysterol (Drisdol) is primarily characterized by the risk of Hypercalcemia (elevated calcium levels in the blood), which is listed as a very common event when the drug's therapeutic range is exceeded. This elevated calcium is the cause of nearly all documented adverse reactions and is classified as the principal mechanism of toxicity.


Adverse Reaction Scope

Adverse reactions are formally grouped by the physiological systems affected by chronic calcium imbalance. Early signs of hypercalcemia, which can be seen in gastrointestinal and nervous system disorders, include anorexia, nausea, vomiting, constipation, headache, and weakness. More serious consequences of prolonged or severe toxicity are classified under the following System-Organ Classes:

  • Renal and Urinary Disorders: Nephrocalcinosis and Irreversible Renal Insufficiency.
  • Vascular and Cardiac Disorders: Generalized Vascular Calcification and Cardiac Arrhythmias.
  • Musculoskeletal Disorders: Bone demineralization (Osteoporosis) in adults.

Safety Classifications and Restrictions

Serious Adverse Reactions documented in regulatory sources include irreversible renal insufficiency and generalized soft tissue calcification, which may result in death. The drug's effects are known to persist for two or more months following discontinuation, emphasizing the slow reversibility of its toxic potential.

Use of Drisdol is strictly Contraindicated in individuals with pre-existing Hypercalcemia, Hypervitaminosis D, or Malabsorption Syndrome. Furthermore, hypercalcemia induced by the drug can enhance the toxic effect of cardiac glycosides.

Population-Specific Safety: For the Pediatric Population, official labeling notes a risk of decline in linear growth and increased bone mineralization, potentially resulting in Dwarfism. During Pregnancy and Lactation, the potential for fetal damage and excretion of the drug into breast milk is noted due to the risk of hypercalcemia in the fetus or nursing infant.

These classifications structure the understanding of the drug’s risks by focusing almost exclusively on the degree and duration of elevated calcium levels, establishing the need for tight control to prevent serious effects on the kidneys and soft tissues. This framework confirms the compound’s potent, long-acting nature.

Overdose and Emergency Response

Overdosage of Dihydrotachysterol is characterized by clinical manifestations of severe hypercalcemia, as documented in regulatory information. Early symptoms include general signs such as weakness, headache, loss of appetite, nausea, and vomiting, alongside increased thirst (polydipsia) and frequent urination (polyuria). Physiological findings confirming overdosage include elevated levels of calcium and phosphorus in the serum and urine, as well as indications of renal impairment like azotemia.

Regulatory documents specify that severe overdosage can lead to life-threatening outcomes. These include the widespread calcification of soft tissues, particularly the heart, blood vessels, and kidneys, potentially progressing to cardiovascular or renal failure. An acute, severe escalation is classified as a Hypercalcemic Crisis.

Immediate action mandated by regulatory authorities involves the immediate withdrawal of Dihydrotachysterol. Urgent medical attention must be sought when the resulting progressive hypercalcemia is severe enough to necessitate emergency intervention. There is no specific antidote listed in the official labeling; therefore, management is supportive, focusing on measures like liberal fluid intake, bed rest, and adherence to a low calcium diet, coupled with rigorous monitoring of serum calcium levels until they return to normal. Special consideration is noted for overdosage during pregnancy and breastfeeding due to the risk of hypercalcemia in the newborn or infant.

Therapeutic Uses of Drisdol

Quick Facts

  • Hypoparathyroidism: Used in the management of this condition.
  • Refractory Rickets: May be administered for this type of rickets, also known as vitamin D-resistant rickets.
  • Familial Hypophosphatemia: Used as part of the therapeutic approach for this inherited condition.

Drisdol (ergocalciferol) is indicated for prescription use in the treatment and support of several specific health conditions. The primary therapeutic domains include those related to disorders of calcium and phosphate regulation.

The medication is used to support the management of hypoparathyroidism, a condition resulting from decreased functioning of the parathyroid glands. It is also an administered treatment for refractory rickets, which is a form of rickets that does not show a typical response to standard vitamin D therapy.

Furthermore, Drisdol is indicated for use in addressing familial hypophosphatemia, an inherited disorder characterized by low phosphate levels in the blood. For all of these uses, the drug is intended to contribute to the overall therapeutic plan as determined by a healthcare provider. Close medical supervision and individualized dosage are necessary during administration.

Regulatory References

  1. DailyMed Label for Drisdol

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Drisdol

Official regulatory documents define strict criteria for the use of Drisdol (Dihydrotachysterol), primarily based on a patient’s existing mineral balance.


Populations for Whom Use is Contraindicated

Use of Drisdol is absolutely prohibited in patients presenting with excessively high mineral levels, as this would exacerbate toxicity. Contraindications include documented Hypercalcemia (high blood calcium), Hypervitaminosis D (excess Vitamin D levels), and Malabsorption Syndrome. Use is also contraindicated in individuals with known Hypersensitivity to the drug or its components.


Populations Requiring Conditional Use or Caution

The medicine is approved for use in both adult and pediatric patients for its specific indications. However, pediatric doses require extreme care and individualization, as the range between effective and toxic levels is narrow. Use in older adults also requires caution and potentially lower initial doses due to the greater likelihood of decreased organ function.

For pregnant individuals, the drug is categorized as Pregnancy Category C by the FDA, meaning it should be used only if the potential benefit justifies the potential risk to the fetus. Lactating individuals are advised to use the drug with caution, as the drug's metabolites pass into breast milk, requiring the infant's calcium levels to be monitored.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Drisdol (Dihydrotachysterol) is a potent Vitamin D Analogue whose interactions primarily stem from its effect on mineral metabolism and its fat-soluble nature, as documented in official regulatory labeling.


Pharmacodynamic and Additive Risks

Classification Interacting Agents Official Interaction Outcome
Major Additive Risk Other Vitamin D Analogs Co-administration is restricted due to the potential for additive hypercalcemic effects and toxicity.
Serious Risk Cardiac Glycosides (e.g., Digoxin) The risk of ventricular arrhythmias is increased, as Dihydrotachysterol-induced hypercalcemia potentiates the action of digitalis drugs.
Additive Effect Thiazide Diuretics These agents can increase the hypercalcemic effect of the analog due to reduced urinary calcium excretion.

Pharmacokinetic and Exposure Effects

Classification Interacting Agents Official Interaction Outcome
Reduced Efficacy Anticonvulsant Agents (e.g., Phenytoin) Efficacy may be reduced because these agents accelerate the metabolic clearance of the drug.
Reduced Absorption Bile Acid Sequestrants The serum concentration of Dihydrotachysterol is decreased due to interference with absorption. Timing separation of doses is required to mitigate this effect.
Absorption Interference Mineral Oil This substance is officially listed as interfering with the absorption of fat-soluble vitamin D preparations.

Population-specific interaction notes exist for patients with Hepatic and/or Biliary Dysfunction, as these conditions can decrease intestinal absorption of the fat-soluble analog. Caution is also noted in Renal Dysfunction due to the risk of calcium-phosphate deposits when hyperphosphatemia is present.

Mechanism of Action

How Drisdol Works: Mechanism of Action

Drisdol (ergocalciferol, or Vitamin D2) functions as an inactive prohormone operating within the body’s endocrine system to affect mineral balance. Its action begins with a two-step hydroxylation process occurring sequentially in the liver and kidneys, converting ergocalciferol into the biologically active hormone, calcitriol (1,25( OH)2 D2).

Calcitriol acts as an agonist, binding to the Vitamin D Receptor (VDR)—a nuclear receptor present in target cells. This receptor-ligand complex functions as a transcription factor, modulating gene expression essential for mineral transport. This molecular action regulates the transport of calcium and phosphate ions; it increases intestinal absorption and enhances renal reabsorption, resulting in the net transfer of these minerals into the bloodstream.

Furthermore, the active metabolite engages the parathyroid hormone (PTH) feedback loop. In response to its effect on serum calcium concentration, the metabolite exerts a negative feedback effect on the parathyroid gland, suppressing PTH secretion. This targeted dampening of the hormonal pathway influences the maintenance of bone matrix turnover.

Dosage and Administration Information

Dihydrotachysterol is administered orally and is supplied in capsule or tablet strengths, including 0.125 mg and 0.2 mg, as well as an oral solution concentrate of 0.2 mg/mL. The official usage pattern involves a two-phase schedule, beginning with a higher initial loading dose followed by a lower, individualized maintenance dose.

For adult regimens, such as for Hypoparathyroidism, the initial oral dose typically ranges from 0.8 mg to 2.4 mg daily for several days. This is followed by a daily maintenance dose ranging from 0.2 mg to 1.0 mg. The long-term dose is highly specific and is adjusted at intervals of four to eight weeks based on the patient’s laboratory results. Usage in infants and children follows distinct, lower dosing guidelines, with specific ranges provided for neonates and older children.

A critical instruction for proper administration is the mandatory co-administration of adequate oral calcium supplements throughout the treatment course. The medicine can be taken with or without food. For the oral solution concentrate, the use of a calibrated dropper is required to ensure accurate measurement. Therapy requires close medical supervision, with frequent monitoring of serum calcium levels to ensure they are maintained within the designated target range of 9 to 10 mg/dL. This monitoring protocol governs the entire dosing adjustment process.

Recent Clinical Evidence

Drisdol (Ergocalciferol): Recent Clinical Evidence


Ergocalciferol (Vitamin D2), the active ingredient in Drisdol, is a form of vitamin D used to address deficiency states and conditions related to impaired calcium and phosphate balance.

Clinical research regarding ergocalciferol focuses primarily on its role in correcting vitamin D deficiency and managing specific bone disorders. The product is indicated for use in the management of hypoparathyroidism, refractory rickets (vitamin D-resistant rickets), and familial hypophosphatemia.

Repletion of Vitamin D Status

Clinical trials consistently show that ergocalciferol supplementation is associated with an increase in serum 25-hydroxyvitamin D [25(OH)D] levels, which are commonly used to assess the body's vitamin D status. A weekly regimen of high-dose ergocalciferol for a defined period has been observed to effectively raise these circulating levels in populations with insufficiency or deficiency.

However, some systematic reviews and meta-analyses suggest that cholecalciferol (Vitamin D3) may demonstrate a greater efficacy compared to ergocalciferol (Vitamin D2) in raising and maintaining serum 25(OH)D concentrations. Conflicting results persist in the literature regarding the relative effectiveness of the two forms of vitamin D.

Effects on Mineral Metabolism

In studies involving subjects with low vitamin D levels, the administration of ergocalciferol has been associated with changes in mineral homeostasis. Research indicates that correcting low vitamin D status with ergocalciferol may influence serum levels of parathyroid hormone (PTH) as well as calcium and phosphorus. This relationship is complex, and the precise effects can vary based on the patient population and the duration of therapy. Adequate dietary calcium intake is frequently noted in the literature as being necessary for a favorable response to ergocalciferol therapy related to bone health.

Frequently Asked Questions (FAQ)

Common questions about Drisdol (FAQ)

Q: Are there any dietary restrictions while taking Drisdol?

Official regulatory information states that a patient's dietary intake of calcium, phosphate, and vitamin D may need adjustment while using this medicine. Official information notes that an abrupt increase in dietary calcium should be avoided. Official documents also note that consuming grapefruit or grapefruit juice may alter drug levels in the body.

Q: What is the difference between Drisdol and calcium supplements?

Drisdol is classified as a potent Vitamin D Analogue and acts as a calcium regulator to promote the absorption and mobilization of minerals. Calcium supplements, in contrast, provide the necessary mineral source that official documents describe as necessary for co-administration for the treatment to be effective.

Q: Can Drisdol be taken with other vitamins?

Official documents indicate that a healthcare provider should be informed about all vitamins, supplements, and other medicines used. This helps the provider monitor for and prevent potentially harmful additive effects, particularly the risk of dangerously high calcium levels when taken with other forms of Vitamin D.

Q: Can Drisdol cause dizziness or confusion?

Official safety information indicates that dizziness and mental confusion are recognized signs associated with hypercalcemia (excessively high calcium levels in the blood). Hypercalcemia is the principal toxicity risk of the medicine, which highlights the necessity of the established monitoring protocol.

Q: How long is a person typically on Drisdol?

Official clinical and regulatory literature describes the active ingredient's effect as having a relatively slow onset and slow offset. Studies indicate the effect on mineral levels can persist in the body for approximately seven to twenty-one days after the medicine is discontinued.

Q: Is Drisdol the same as Vitamin D3 (cholecalciferol)?

Dihydrotachysterol (Drisdol) is a synthetic Vitamin D Analogue that is chemically distinct from the naturally occurring Vitamin D3 (cholecalciferol). DHT is a derivative that does not require the final metabolic activation step in the kidney, unlike many other forms of Vitamin D.

Q: Why is it important to know my baseline vitamin D level before starting Drisdol?

Regulatory documents confirm that Drisdol is used under close medical supervision and highly individualized dosing due to its narrow therapeutic range. Frequent monitoring of key lab results, including calcium, phosphorus, and PTH levels, is part of the established protocol used to guide initial and ongoing dosage adjustments and to prevent toxicity.

Q: What information is available about long-term use of Drisdol?

Long-term use is associated with an established protocol of frequent monitoring of mineral levels in the blood. Prolonged, uncontrolled exposure can lead to serious adverse reactions, including generalized calcification of soft tissues and blood vessels, as well as irreversible kidney damage.

Q: Is Drisdol the same as over-the-counter Vitamin D supplements?

According to official regulatory classification, this medicine is designated as a prescription drug. This is due to its potent, long-acting nature and its narrow therapeutic index (the small difference between a helpful dose and a toxic dose), which is associated with a requirement for continuous medical supervision. Many over-the-counter supplements do not carry this same safety restriction.

Q: How quickly can a person expect to feel the effects of Drisdol?

Clinical information indicates that the active ingredient begins to show its onset of action within four to seven days of starting therapy. The peak effect on the body's mineral levels is typically observed after approximately one month of daily administration.

Q: What is the significance of Drisdol being a prescription-only medicine?

The medicine is classified as a prescription drug because its therapeutic index is narrow—the difference between an effective dose and a dose that causes toxicity is small. For this reason, official safety protocols describe continuous, close medical supervision as part of the safety protocol with frequent lab tests to ensure patient safety.

Q: Can I take antacids while using Drisdol?

Official labeling notes that the use of antacids containing magnesium or calcium should be avoided. Furthermore, chronic use of antacids containing aluminum in combination with this medication may lead to aluminum accumulation and possible toxicity.

Q: Does Drisdol affect sleep?

Regulatory safety documents do not list sleep or insomnia as a common side effect of therapy. However, the side effect profile notes that drowsiness (somnolence) can be an early sign associated with hypercalcemia (high calcium levels), which indicates toxicity.

Q: Can Drisdol interact with herbal supplements?

Official patient information states that a healthcare provider should be informed about all herbs and supplements used, as some may increase the risk of hypercalcemia or be hepatotoxic.

Q: What should a patient do if they suspect an interaction?

Official regulatory guidance indicates that a healthcare provider or physician should be contacted immediately if a patient's condition changes or if they experience early symptoms of toxicity. Official information also notes that prescribed medication should not be stopped without first consulting a doctor.

Q: Does Drisdol contain lactose or other common allergens?

Known hypersensitivity (severe allergy) to the drug or its components is listed as a contraindication to use. Furthermore, some formulations of related vitamin D products are noted to potentially contain tartrazine, which is a substance that may cause allergic reactions in some individuals.

Q: Does Drisdol help with mood or fatigue?

The therapeutic effect of the medicine on general mood is not addressed in official documents. However, the regulatory side effect profile notes that signs of toxicity, specifically fatigue and weakness, are among the early symptoms associated with hypercalcemia (elevated calcium levels).

How should Drisdol be stored and disposed of?

How to Store and Dispose of Drisdol (Ergocalciferol)

Official regulations require Drisdol capsules and solution to be stored at Controlled Room Temperature, defined as 25 C (77 F), with allowable excursions between 15 C and 30 C (59 F to 86 F). The medication must be protected from light and dispensed in a tight, light-resistant container due to the light sensitivity of ergocalciferol.

Keep the product in its container, tightly closed, and out of the reach of children. Avoid exposure to freezing, excess heat, or moisture. To dispose of unused or expired Drisdol, do not flush it down a toilet or throw it in household trash. Instead, patients should ask a healthcare professional or pharmacist for instructions on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drisdol  found in:

A-Z Index: